RU2603050C2 - Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией - Google Patents

Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией Download PDF

Info

Publication number
RU2603050C2
RU2603050C2 RU2013145498/14A RU2013145498A RU2603050C2 RU 2603050 C2 RU2603050 C2 RU 2603050C2 RU 2013145498/14 A RU2013145498/14 A RU 2013145498/14A RU 2013145498 A RU2013145498 A RU 2013145498A RU 2603050 C2 RU2603050 C2 RU 2603050C2
Authority
RU
Russia
Prior art keywords
hyperuricemia
diacerein
gout
uric acid
group
Prior art date
Application number
RU2013145498/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2013145498A (ru
Inventor
Маннчинг Шерри КУ
Чих-куанг ЧЭНЬ
Вэй-Шу ЛУ
И-Инь ЛИНЬ
Original Assignee
ТиДаблЮАй БАЙОТЕКНОЛОДЖИ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТиДаблЮАй БАЙОТЕКНОЛОДЖИ, ИНК. filed Critical ТиДаблЮАй БАЙОТЕКНОЛОДЖИ, ИНК.
Publication of RU2013145498A publication Critical patent/RU2013145498A/ru
Application granted granted Critical
Publication of RU2603050C2 publication Critical patent/RU2603050C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2013145498/14A 2011-03-11 2012-03-07 Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией RU2603050C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11
US61/451,600 2011-03-11
PCT/US2012/027993 WO2012125359A1 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Publications (2)

Publication Number Publication Date
RU2013145498A RU2013145498A (ru) 2015-04-20
RU2603050C2 true RU2603050C2 (ru) 2016-11-20

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013145498/14A RU2603050C2 (ru) 2011-03-11 2012-03-07 Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией

Country Status (16)

Country Link
US (1) US8865689B2 (enExample)
EP (1) EP2683372B1 (enExample)
JP (1) JP6012639B2 (enExample)
KR (1) KR101567885B1 (enExample)
CN (1) CN103429236B (enExample)
AR (1) AR085662A1 (enExample)
AU (1) AU2012229443B2 (enExample)
BR (1) BR112013022332A2 (enExample)
CA (1) CA2829101C (enExample)
ES (1) ES2634562T3 (enExample)
IL (1) IL228030B (enExample)
MX (1) MX350666B (enExample)
PT (1) PT2683372T (enExample)
RU (1) RU2603050C2 (enExample)
TW (1) TWI505827B (enExample)
WO (1) WO2012125359A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2560310T3 (es) * 2010-04-08 2016-02-18 Twi Biotechnology, Inc. Métodos de uso de diacereína como una terapia concomitante para diabetes
AU2012229443B2 (en) 2011-03-11 2017-03-02 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技（武汉）有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
MX2017013489A (es) * 2015-04-20 2018-05-22 Twi Biotechnology Inc Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
MX373702B (es) 2015-07-01 2020-05-07 Twi Biotechnology Inc Formulaciones topicas de diacereina o rheina y sus usos.
MX2018002049A (es) * 2015-08-17 2018-06-15 Twi Biotechnology Inc Diacereina o sus analogos para inhibir la expresion de proteina como mota relacionada a la apoptosis que contiene un dominio de reclutamiento de caspasa (asc), expresion de dominios de pirina y familia nlr que contienen 3 (nlrp3) y/o formacion de complejo de inflamasoma de nlrp3.
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820154B2 (en) * 2006-10-20 2010-10-26 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009698A (es) * 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
DK2124997T3 (da) * 2006-10-20 2012-08-27 Regeneron Pharma Anvendelse af IL-1-antagonister til behandling af gigt og pseudogigt
EP2471517A3 (en) * 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因（ｄｉａｃｅｒｅｉｎ）之醫藥組合物
AU2012229443B2 (en) 2011-03-11 2017-03-02 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820154B2 (en) * 2006-10-20 2010-10-26 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KITADAI H.K. et al. Effect of oral diacerein (DAR) in an experimental hip chondrolysis model// J.Orthoped.Res. June 2006, 24(6), с.1240-1248. BOILEAU C. et al. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodeling// Arthritis Res Ther. 2008; 10(3) : R71, 10 с. *

Also Published As

Publication number Publication date
EP2683372A4 (en) 2014-08-06
EP2683372A1 (en) 2014-01-15
WO2012125359A1 (en) 2012-09-20
MX350666B (es) 2017-09-12
ES2634562T3 (es) 2017-09-28
BR112013022332A2 (pt) 2017-05-30
KR20140019795A (ko) 2014-02-17
CN103429236A (zh) 2013-12-04
AU2012229443B2 (en) 2017-03-02
IL228030B (en) 2018-01-31
TW201249432A (en) 2012-12-16
PT2683372T (pt) 2017-10-25
KR101567885B1 (ko) 2015-11-10
RU2013145498A (ru) 2015-04-20
MX2013010384A (es) 2013-10-07
AR085662A1 (es) 2013-10-16
NZ614486A (en) 2014-11-28
CA2829101A1 (en) 2012-09-20
US20120232044A1 (en) 2012-09-13
CN103429236B (zh) 2016-09-21
IL228030A0 (en) 2013-09-30
US8865689B2 (en) 2014-10-21
CA2829101C (en) 2019-08-20
JP6012639B2 (ja) 2016-10-25
TWI505827B (zh) 2015-11-01
EP2683372B1 (en) 2017-07-12
JP2014507476A (ja) 2014-03-27
AU2012229443A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
RU2603050C2 (ru) Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией
CA2577233C (en) Pharmaceutical composition containing angiotensin ii antagonist
JP6008974B2 (ja) 痛風発赤の治療方法
CN108882744B (zh) 含有益智提取物的组合物以及益智提取物的用途
JP2007525440A6 (ja) アルドステロン受容体アンタゴニストおよび抗糖尿病剤の組合せ
JP2013528198A (ja) １型糖尿病の処置
CN102834099A (zh) Dgat1抑制剂的用途
CN1771040B (zh) 糖尿病治疗药
US20210290610A1 (en) Combination of fxr agonists
CN102892760B (zh) 非醇性脂肪性肝炎的预防和/或治疗剂
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
US20240285583A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
NZ614486B2 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
JP2025541481A (ja) ナトリウム－グルコース共輸送体－２阻害剤およびアンジオテンシンｉｉ受容体遮断剤を含む非アルコール性脂肪性肝疾患の予防または治療用薬学的組成物
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
JP2017061450A (ja) 痛風発赤の治療方法

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200308